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Neuroprotection may prevent or forestall the progression of incurable eye diseases, such as retinitis
pigmentosa, one of the major causes of adult blindness. Decreased cellular ATP levels may contribute to the
pathology of this eye disease and other neurodegenerative diseases. Here we describe small compounds
(Kyoto University Substances, KUSs) that were developed to inhibit the ATPase activity of VCP
(valosin-containing protein), the most abundant soluble ATPase in the cell. Surprisingly, KUSs did not
significantly impair reported cellular functions of VCP but nonetheless suppressed the VCP-dependent
decrease of cellular ATP levels. Moreover, KUSs, as well as exogenous ATP or ATP-producing compounds,
e.g. methylpyruvate, suppressed endoplasmic reticulum stress, and demonstrably protected various types of
cultured cells from death, including several types of retinal neuronal cells. We then examined their in vivo
efficacies in rd10, a mouse model of retinitis pigmentosa. KUSs prevented photoreceptor cell death and
preserved visual function. These results reveal an unexpected, crucial role of ATP consumption by VCP in
determining cell fate in this pathological context, and point to a promising new neuroprotective strategy for
currently incurable retinitis pigmentosa.
D
espite recent advances in the development of new drugs, there remain many incurable disorders, e.g.
neurodegenerative diseases, ischemic diseases, and chronic inflammation, in which themajor pathology in
the affected organs is early cell death, which occurs long before the death of the individual. Indeed,
currently no drug is available to prevent such early cell death in vivo. If such drugs were available, many of these
disorders, if not all, might be prevented or delayed. In the 1990s, due to a growing, but still imperfect, under-
standing of the molecular bases of apoptotic cell death, caspase inhibitors were developed and were heralded as
miracle drugs, but they were ineffective in preventing cell death in vivo. This might be explained as follows:
caspases determine how cells die but are unable to affect the commitment to cell death. Thus, drugs that could
delay or prevent the commitment to cell death have been actively pursued.
Retinitis pigmentosa, which is caused by a gradual degeneration and loss of photoreceptors, is another
intractable eye disease, and more than 1.5 million patients suffer from progressive visual deterioration with this
disorder. Clinical trials using a neurotrophic factor have been initiated1. In retinitis pigmentosa, involvement of
endoplasmic reticulum (ER) stress has been proposed2,3. Thus, new drugs or compounds with ER stress-reducing
activities may prove to be neuroprotective, and are thus worth investigating for the treatment or prevention of
retinitis pigmentosa.
We have long been working to elucidate the molecular bases of polyglutamine diseases, as informative models
for neurodegeneration. We and other research groups produced several lines of evidence that implicate valosin-
containing protein (VCP), an AAA (ATPases Associated with diverse cellular Activities)-type ATPase with
ubiquitous expression, as a major player causing neurodegeneration. It is notable that VCP is highly conserved
among species; its amino acid sequences are completely identical among mouse, rat, and human, and 84%
identical between human and Drosophila4. We first assumed that specific cellular genes are involved in the
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for genetic analyses. Mutant screening revealed that Ter94 loss-of-
function alleles mitigated polyglutamine-induced eye degeneration4.
Conversely, overexpression of wild-type Ter94 enhanced the poly-
glutamine-induced eye degeneration4. Since the mammalian Ter94
ortholog is VCP, these results raised the possibility that VCP is
involved in the pathogenesis of human neurodegenerative diseases5.
Consistent with this possibility, VCP mutations were identified that
are causative for IBMPFD (inclusion bodymyopathy associated with
Paget disease of bone and frontotemporal dementia)6, a human her-
editary disease with dementia, or for rare cases of familial amyo-
trophic lateral sclerosis (ALS)7. In our evaluation, all tested
pathogenic VCPs possessed elevated ATPase activities, as compared
with wild-type VCP8, indicating that the constitutive elevation of its
ATPase activity may be pathogenic.
These lines of evidence suggested that inhibitors of the ATPase
activity of VCP could protect neuronal cells. In addition to its
ATPase activity, however, many cellular functions of VCP have been
proposed9–11, e.g., proteasome-mediated protein degradation, endo-
plasmic reticulum-associated degradation (ERAD), cell cycle con-
trol, membrane fusion, maintenance of the Golgi apparatus,
protein trafficking, autophagy, genomic DNA surveillance, etc.,
some of which are crucial for cell survival. Indeed, VCP knockdown
and overexpression of dominant-negative forms of VCP showed
toxicity in cultured cells12,13. DBeQ, a recently reported VCP inhib-
itor (in vitro IC50 (half maximal inhibitory concentration) 1 mM)14,
also showed cellular toxicity. Given that VCP has multiple cellular
functions, some of them would require ATP hydrolysis and others
would not. Thus, it is a challenge to find small compounds that can
inhibit or reduce the ATPase activity of VCP without incurring the
general toxicity caused by loss of crucial cellular functions of VCP.
Results
KUSs inhibited VCP ATPase activity but not VCP cellular
functions. In our search for novel VCP ATPase inhibitors, we
found that a naphthalene derivative can inhibit the ATPase activity
of VCP with no apparent toxicity at 10 mM on cultured cells. Based
on the chemical structure, about two hundred compounds were
newly synthesized and named KUSs (Kyoto University substan-
ces). Some of them, e.g. KUS31, 69, 94, 121, and 187, clearly
inhibited the ATPase activity of recombinant VCP in vitro with
IC50 values ranging from approximately 100 nM to 1 mM (Fig. 1a).
These IC50 values were equivalent to or much lower than that of
DBeQ14, whose reported IC50 is 1 mM (Supplementary Fig. 1). It is
notable that KUSs very mildly inhibited the ATPase activity of N-
ethylmaleimide-sensitive fusion protein (NSF) (Fig. 1b), whose
structure is most closely related with that of VCP.
We then examined the effect of KUS31, 69, 94, 121, and 187 on
VCP functions in cultured cells. We also used DBeQ as a reference
compound. As reported, DBeQ induced accumulation of ubiquiti-
nated proteins, ER stress, autophagy, and eventually cell death
(Fig. 1c and d). Surprisingly, these compounds did not induce any
of these phenotypes (Fig. 1c and d). These results clearly indicated
that ATPase inhibition by KUS31, 69, 94, 121, and 187 (referred to as
‘‘KUSs’’ hereafter, for simplicity) did not interfere with reported
cellular VCP functions (referred to as ‘‘VCP functions’’ hereafter),
indicating that VCP functions do not necessarily require its ATPase
activity (see Discussion).
KUSs protected cells under ER stress-inducing conditions.
Additionally, KUSs protected cells from several cell death-inducing
insults. For example, when HeLa cells were cultured under low
glucose conditions (0.2 g/l of glucose), all cells died within several
days (Fig. 2a). However, when KUSs were present in the media, they
prevented cell death (Fig. 2a and b). Protective effects were also
observed when HeLa cells were treated with tunicamycin (Tm)
(Fig. 2c), or when HEK293 cells were subjected to serum-free
conditions (Fig. 2d). These protective effects of KUSs were dose-
dependent, as exemplified by KUS121 (Fig. 2e). These data clearly
implied that inhibition of VCP ATPase activity by KUSs could
protect cells from several cell death-inducing insults.
Tunicamycin treatment and glucose starvation are known to cause
ER stress and to lead to cell death. C/EBP-homologous protein
(CHOP) is a core mediator of ER stress-induced cell death, and is
upregulated during ER stress15. Indeed, KUSs suppressed the
expression of CHOP in tunicamycin-treated HeLa cells (Fig. 2f).
KUSs also suppressed the expression of 78 kDa glucose-regulated
protein (Grp78), another ER stress marker16, in the tunicamycin-
treated cells. Next, we examined Akt (serine/threonine-protein
kinase) activation by examining its phosphorylation at Ser473, which
has been reported to be necessary and sufficient for cell survival17.
The phosphorylated Akt signal nearly disappeared in cells treated
with tunicamycin, but was clearly detected in cells treated with tuni-
camycin and KUSs (Fig. 2f). These data indicate that KUSs could
suppress ER stress and promote cell survival, whichwas evidenced by
Akt being in an activated state.
Because VCP is a major ATPase in cells, we then examined the
contribution of VCP to total ATPase activities in clarified whole cell
lysates, and found that VCP appeared to contribute to approximately
20%–40% of the total collective ATPase activity, depending on the
cell types and culture conditions (an example is provided in Fig. 3a).
In neuronally differentiated PC12 cells, for example, 100 nM and
1 mM KUS121, as well as KUS187, significantly lowered the total
ATPase activity (approximately 20% and 40% for both concentra-
tions, respectively) (Fig. 3a). Given that the IC50 values of KUS121
and KUS187 on recombinant VCP were around 200 , 300 nM
(Fig. 1a), these data implied that the ATPase activity of VCP con-
tributed to as much as 40% of the total soluble ATPase activities in
the cell lysate. This estimation was further supported by the obser-
vation that 1 mM KUS94 (IC50 is 1 mM) also showed approximately
20% suppression of the soluble ATPase activities (Fig. 3a). Consistent
with the inability of KUS11 to inhibit the ATPase of VCP in vitro
(IC50 is more than 100 mM), KUS11 did not show any significant
inhibition of total ATPase activity in the clarified lysates (Fig. 3a).
We next examined whether KUSs altered cellular ATP levels. At
20 hours after a change to low glucose medium (0.25 g/l), glucose
concentrations in the medium approached zero, and ATP levels in
the cells (control cells) significantly decreased (Fig. 3b). In contrast,
ATP levels in the cells with low glucose medium plus KUSs remained
significantly higher than those in the control cells (Fig. 3b and
Supplementary Fig. 2a). In addition, in KUS-treated cells, the ratio
of ATP to ADP was higher than in the control cells (Supplementary
Fig. 2b). These data indicate that KUSs suppress consumption of
ATP in cells under stress conditions. Interestingly, acetyl-CoA levels
in the KUS-treated cells were significantly lower than those in the
control cells (Fig. 3c and Supplementary Fig. 2c), suggesting the
possibility that KUSs may induce a metabolic shift from a glycolytic
pathway tomitochondrial pathways to produce ATP. This possibility
remains to be clarified. The low levels of acetyl-CoA might also
contribute to protect cells from cell death, as reported recently18.
KUSs and exogenous ATP both prevented ER stress in cultured
cells. It has long been believed that ER stress is induced by the
accumulation of misfolded proteins, or protein aggregates, in the
ER19–21. We recently identified laminin c1 as an aggregation-prone
protein in the ER.We therefore examined laminin c1 as an indicator
of ER-stress in tunicamycin-treated cells. By immunocytochemical
analyses, expression of laminin c1 was observed in a diffuse pattern
throughout the ER in normal cells (Control in Fig. 4a). When cells
were treated with tunicamycin, laminin c1 formed clear aggregates
(DMSO in Fig. 4a). However, not only 50 mMKUSs (KUS69, 94, 121,
and 187) but also 1 mM ATP treatments clearly prevented the
aggregation of laminin c1 (Fig. 4a). Consistent with these results,
www.nature.com/scientificreports
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KUSs and ATP treatments similarly prevented decreases of ATP
levels in tunicamycin-treated cells (Fig. 4b). By contrast, KUS11,
which could not inhibit VCP ATPase, was unable to prevent the
tunicamycin-elicited ATP decrease (Fig. 4b). It is notable that the
addition of 0.1 mM ATP or 3 to 10 mM methylpyruvate (weakly
membrane-permeable pyruvate, which is converted to ATP in mito-
chondria) were also ineffective in preventing the aggregation of
laminin c1 (Fig. 4a), but could nevertheless dampen the induction
of ER stress, namely CHOP induction (Fig. 4c). These results
indicated that the ER is more sensitive to decreases in ATP levels
than to the presence of aggregates (see Discussion).
KUSs mitigated pathologies of rd10, a mouse model of retinitis
pigmentosa. As we have long been seeking a new strategy to protect
retinal neuronal cells, we were intrigued by the observation that VCP
was highly expressed in all types of retinal neuronal cells (Supple-
mentary Fig. 3). Furthermore, in retinitis pigmentosa, an involve-
ment of ER stress has been proposed2,3. After confirming the
neuroprotective efficacy of KUS in retinal organ culture (Supple-
mentary Fig. 4), we then examined whether the protective effects
would be observed in vivo against the degeneration of photo-
receptor cells. For this purpose, rd10 mice were used as a repre-
sentative mouse model of retinitis pigmentosa22. Rd10 mice have a
mutation in a gene encoding the rod cyclic guanosine monophos-
phate (cGMP) phosphodiesterase beta subunit (PDE6B)22, which is
also mutated in patients with retinitis pigmentosa. The mice have
been commonly used to test the efficacies of new treatments,
including gene therapy, neuroprotectants, and stem cell derived
retinal cells.
Starting 7 days after birth, KUS121 or KUS187 was administered
daily (50 mg/kg) by intraperitoneal injection. Spectral-domain
optical coherence tomography (SD-OCT) examination showed that
at age 21 days, the retinas of the control rd10 mice had begun to
degenerate (Supplementary Fig. 5a). To test the visual function of the
mice, dark-adapted electroretinograms were recorded. The ampli-
tude of the a-wave, which represents visual function of photorecep-
tors, was smaller in the control mice than in the KUS-treated mice
(Supplementary Fig. 5b and c). The peak latency of the a-wave, which
negatively correlates with visual function of photoreceptors, was
delayed in the control mice as compared with the KUS-treated mice
Figure 1 | Structures and characterization of KUSs, novel VCPmodulators. (a) Structures and IC50 values of KUS11, KUS31, KUS69, KUS94, KUS121,
and KUS187. Note that KUS11 did not inhibit the ATPase activity of recombinant VCP, and it did not share a common structure with the other KUSs.
(b) ATPase activity assays of recombinant human NSF, comparing KUSs and DBeQ. (c) Immunoblot analysis of ubiquitinated proteins, an ER stress
marker (CHOP), and an autophagy indicator (LC3), comparing KUSs andDBeQ. As a control, MG132, a proteasome inhibitor, was used for the analysis.
Actin served as a loading control. Complete scans of the different blots are presented in Supplementary Fig. 7. (d) Comparison of KUSs and DBeQ
for cell death-inducing activities. HeLa cells were treated with 50 mM DBeQ or KUSs for 24 hours.
www.nature.com/scientificreports
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(Supplementary Fig. 5d). At age 25 days, the thinning of the outer
nuclear layer (ONL) was clearly observed in the control mice
(Fig. 5a). The outer nuclear layer and the junction line between the
inner segment and outer segment (arrow heads in Fig. 5a), which is
generally considered to be positively associated with visual func-
tion23,24, were clearly detected in the KUS-treated but not in control
mice. A very small electroretinogram response was observed in con-
trol mice, but an almost normal electroretinogram response was
observed in most of the KUS-treated mice (Fig. 5b). At age 29 days,
the photoreceptor layer was barely detected in SD-OCT images, and
electroretinogram records were almost flat in control mice. In the
age-matched KUS-treated mice, the outer nuclear layer, although
thin, and an electroretinogram response were still observed (Fig. 5c
and d). By histological examination, at age 33 days, the outer nuclear
layer in the control mice consisted of only 1–2 rows of cells, but there
remained 5–6 rows of cells in the outer nuclear layer in the KUS-
treated mice (Fig. 5e). In KUS-treated but not control mice, the outer
segment of the photoreceptors was observed (Fig. 5e). The electro-
retinogramwas non-recordable in the controlmice, but small b-wave
and oscillatory potentials were observed in the KUS-treated mice
(Fig. 5f). Time-dependent changes in total retinal thickness mea-
sured on SD-OCT images (Fig. 5g) and in b-wave amplitudes of
dark-adapted electroretinogram (Fig. 5h) showed that KUS treat-
ments had the potential to prevent or delay the disease progression.
b-wave amplitudes of dark-adapted electroretinograms in non-
treated wild-type mice mostly remained unchanged or slightly
Figure 2 | Prevention of cell death and ER stress by KUSs. (a) Photographs of HeLa cells, cultured with DMSO (DMSO) or KUSs (KUS94, KUS121,
andKUS187, 20 mMeach) for 41 hours in low glucose (0.2 g/l)medium. Scale bar, 100 mm. (b–e)WST (water-soluble tetrazolium salts) values reflecting
relative live cell numbers are shown, as optical density (OD) at 450 nm. Error bars indicate SD. (b) WST values of HeLa cells, cultured in low glucose
(0.2 g/l) with DMSO (control) or KUSs (50 mM for KUS121; 20 mM for KUS69, KUS94, and KUS187, n5 3) for 41 hours. (c) Cell viability, indicated by
WST values of HeLa cells, cultured with tunicamycin (Tm) (0.2 mg/ml) for 41 hours with KUSs (20 mM each, n5 3). (d) WST values of HEK293 cells,
cultured under serum-free conditions for 65 hours with DMSO (control) or KUSs (20 mM each, n 5 3). *** P , 0.001, vs. DMSO control
(Dunnett’s test). (e)WST values of HeLa cells, cultured in low glucose (0.2 g/l)mediumwith different concentrations of KUS121 (5, 10, 20, and 50 mM, n
5 3) for 41 hours. ** P 5 0.008, *** P , 0.001, vs. DMSO control (Dunnett’s test). (f) Western blot analysis of HeLa cells, treated with tunicamycin
(Tm, 0.5 mg/ml) with DMSO (control) or KUSs (50 mM each, KUS69, KUS94, KUS121, and KUS187) for 5 hours. Complete scans of the different
blots are presented in Supplementary Fig. 8.
www.nature.com/scientificreports
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increased at the age of 33 days (Supplementary Fig. 6a). Note that
KUS administration in adult wild-type mice did not induce any
significant change in the amplitude of a- and b-waves (Supple-
mentary Fig. 6b and c). When examined by electron microscopy,
the outer segment of the control mouse retina was mostly disar-
ranged at the age of 21 days (Fig. 6a and c), whereas that of KUS-
treated mouse retina was regularly arranged (Fig. 6b and d). In rd10
mice, KUS treatments apparently suppressed CHOP expression, as
observed in cultured cells (Fig. 5i).
Discussion
We successfully developed novel ATPase inhibitors for VCP, with a
naphthalene-derived structure in common, andwe collectively called
themKUSs (Kyoto University substances). KUSs showed IC50 values
from 100 nM to 1 mM for the inhibition of ATPase activities of
recombinant VCP in vitro. Totally different from known ATPase
inhibitors for VCP, e.g. DBeQ14, NMS-87325, etc., KUSs, e.g.
KUS31, KUS69, KUS94, KUS121, KUS187, etc., did not manifest
any apparent cellular toxicity, up to 50 mM, on essentially all tested
cultured cells; nor did they elicit any aberrant phenotypes that would
be expected from the inhibition of cellular VCP functions. These
results demonstrated that KUSs could inhibit VCP ATPase activity
without inhibiting cellular VCP functions. AAAATPasesmight have
additional functions that are independent of their ATPase activity.
Recently, Noi et al. analyzed the natural movement of recombinant
VCP by high-speed atomic force microscopy and demonstrated that
ATP-binding mutants of VCP did not display any apparent rota-
tional movement in solution, but wild-type VCP and ATP-
hydrolysis mutants of VCP were indistinguishably capable of rota-
tional movements26. These data are consistent with the idea that, for
at least some VCP functions, ATP binding is essential but ATP
hydrolysis is not. This idea is reminiscent of G proteins and actin,
whose functions require guanosine triphosphate (GTP) and ATP
binding, respectively, but not GTP and ATP hydrolysis, respectively.
KUSs likely inhibit the ATPase activity of VCP, but not necessarily
VCP functions related to binding of ATP.We thus categorized KUSs
as ‘‘VCP modulators’’ rather than ‘‘VCP inhibitors’’.
Surprisingly, KUSs were able to reduce by approximately 40% the
total ATP consumption in whole cell soluble lysates of neuronally
differentiated PC12 cells, raising the possibility that VCP accounts
for approximately 40% of the ATP consumption among soluble
ATPases in the non-dividing PC12 cells. This result led us to specu-
late that KUSs would significantly reduce ATP consumption in living
cells as well. Indeed, in cultured cells, KUSs were shown to maintain
ATP levels in starved conditions as well as in conditions with
enhanced ATP consumption, such as in tunicamycin-induced ER
stress27. Consistently, and surprisingly, KUSs and ATP similarly sup-
pressed tunicamycin-induced ER stress and eventually cell death.
More surprisingly, KUSs (at 50 mM) and ATP (at 0.3 to 1 mM)
similarly prevented the aggregation of laminin c1 in tunicamycin-
treated HeLa cells. It is noteworthy that a low level of ATP (at
0.1 mM) and methylpyruvate (at 3 to 10 mM) were not able to
Figure 3 | Effects of KUSs on ATPase activities, ATP levels, and acetyl-CoA levels. (a) Inhibition of ATPase activity in clarified whole cell lysates by
KUS121, KUS187, and KUS94, but not KUS11. Total ATPase activities in clarified whole cell lysates from differentiated PC12 cells were measured in the
absence and presence of KUSs. Relative ATPase activities are shown with values in the absence of KUS (D: DMSO) set at 100%. (b) HeLa cells were
cultured in medium with low glucose (0.25 g/l) for 20 hours, with or without KUSs, and ATP levels were measured with luciferase assays. (c) HeLa cells
were cultured in medium with low glucose (0.25 g/l) for 20 hours, with or without KUSs, and acetyl-CoA levels were measured. * P, 0.05, ** P, 0.01,
*** P , 0.001 vs. DMSO control (Dunnett’s test, n 5 3).
www.nature.com/scientificreports
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prevent the aggregation of laminin c1, but were nevertheless able to
reduce the induction of CHOP, a well-known ER stress marker, in
tunicamycin-treated cells. This observation clearly supports the idea
that ER stress is more directly elicited by a decrease of ATP than the
presence of aggregated proteins in the ER. Historically, most ER
chaperones were originally identified as proteins induced by glucose
starvation and thus were named as GRP (glucose-regulated pro-
teins)28. Moreover, it has recently been shown that the binding of
ER stress sensors, such as PRKR-like endoplasmic reticulum kinase
(PERK) and inositol-requiring enzyme-1 (Ire1), to Grp-78 (Bip) is
ATP-dependent29. Thus, it is likely that a decrease in the ATP level in
the ER induces the dissociation of Bip from the ER-stress sensors,
leading to their self-oligomerization and subsequent activation.
The evidence that KUSs could prevent the decrease in ATP level in
response to several cell death-inducing insults, and eventually cell
death, led us to examine the possibility that KUSs would function as
cell-protecting compounds in pathological conditions, and that the
prevention of early cell death could in turn prevent or delay the
deterioration of the affected organs. For this purpose, we chose
rd10, a mouse model of retinitis pigmentosa. Currently, it is very
difficult to quantitatively measure local ATP levels, and thus we
examined whether KUSs could prevent neuronal cell death in the
affected retinas.
In rd10 mice, in which the rod cGMP phosphodiesterase beta
subunit (PDE6B)22 is mutated, KUSs significantly retarded the pro-
gress of photoreceptor cell death, and protected the photoreceptor
cells morphologically as well as functionally. Reduction of ER stress
would be a likely mechanism for KUS-mediated protection of photo-
receptors, although our current data are not sufficient to exclude
other yet-unknown possibilities. In retinitis pigmentosa, neuropro-
tective treatment is regarded as an important future therapeutic
strategy, and several clinical trials to prolong the viability of the
retinal neuronal cells have been ongoing1. We are also planning to
initiate clinical studies using KUSs in the near future.
Considering all of the data together, we posit that a reduction of
ATP levels is a common condition in the affected organs of incurable
Figure 4 | KUSs and ATP each prevented a decrease of ATP levels and ameliorated ER stress in tunicamycin-treated cells. (a) Immunocytochemical
analyses of HeLa cells by an anti-laminin c1 antibody. HeLa cells were treated with 0.5 mg/ml of tunicamycin (Tm) for 5 hours in the presence of KUSs
(50 mM), ATP (0.1, 0.3, and 1 mM), methylpyruvate (MePyr) (3 and 10 mM), or vehicle alone (DMSO). Then, cells were fixed and subjected to
immunocytochemical analyses. Normally growing HeLa cells were also analyzed (Control). Scale bar, 10 mm. (b) Measurements of the relative amounts
of ATP per cell. HeLa cells were treated with tunicamycin (Tm, 0.5 mg/ml) for 24 hours in the presence of KUSs (50 mM) or ATP (0.1 and 1 mM), or
vehicle alone (DMSO), and were harvested. Then, ATP amounts from 1.53 105 cells were measured27. * P, 0.05, ** P, 0.01. Error bars indicate SD.
(c) Western blot analyses on CHOP. HeLa cells were treated with 0.5 mg/ml of tunicamycin for 5 hours in the presence of KUSs (50 mM), ATP (0.1, 0.3,
and 1 mM),methylpyruvate (MePyr) (3 and 10 mM), or vehicle alone (-). Then, cells were harvested and subjected to western blot analyses. Actin served
as a loading control. Complete scans of the different blots are presented in Supplementary Fig. 9.
www.nature.com/scientificreports
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disorders with early cell death. Becausemany proteins require ATP, a
reduction of ATP levels would contribute to a functional decline in
affected cells or organs in early stages of the disease, which might
precede cell death. Reducing ATP consumption by way of KUSs and/
or enhancing ATP generation by yet-unknown compounds would be
a novel strategy to retard these processes and thus to prevent or
retard the progression of clinical manifestations. Recently, the
involvement of translational suppression via phosphorylation of
eIF2a has been proposed in the pathogenesis of Alzheimer30 and
prion diseases31. Indeed, novel PERK inhibitors showed significant
efficacies in a mouse prion disease model32. Given that PERK is the
kinase responsible for the phosphorylation of eIF2a in ER stress, the
effect of KUSs in these disease models would be worth evaluating.
In conclusion, we showed that KUSs, new compounds developed
as ATPase inhibitors of VCP, have novel functions as ‘‘VCP mod-
ulators’’ or ‘‘ATP regulators’’ without apparent inhibition of cellular
VCP functions. These new ‘‘ATP regulators’’ have strong neuropro-
tective effects in vivo on retinal photoreceptor cells. The efficacies
were apparently correlated with their abilities to suppress ER stress.
To the best of our knowledge, KUSs are the first small chemicals that
can prevent cell death in an animal model of human retinitis pig-
mentosa. Given that the major pathology of many other incurable
human disorders, e.g. neurodegenerative diseases, ischemic diseases,
etc., is also early cell death, KUSsmay provide a novel strategy for cell
protection in such incurable disorders.
Methods
Cell culture. HeLa, HEK293, and PC12 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum. Tunicamycin (0.2–2 mg/ml,
Nacalai Tesque, Kyoto, Japan) was added to induce ER stress. Viability of cultured
cells was measured by formazan production with an ARVO multilabel counter
(Wallac), using WST (water soluble tetrazolium salts)-8 reagent (Cell count reagent
SF, Nacalai Tesque, Kyoto, Japan). ATP in cultured cells was measured by luciferase
activities with an ARVO multilabel counter, using ATP assay reagent for cells (Toyo
B-net, Tokyo, Japan). Acetyl-CoA was measured using a PicoProbe Acetyl CoA assay
kit (BioVision, CA, USA) with a Spectra Max multilabel counter (Molecular Devices,
CA, USA).
Measurement of ATPase activities. We measured ATPase activities by modifying
the molybdate assay, which was as described previously8. In the assay, 1 mg of whole
cell soluble lysate of neuronally differentiated PC12 cells, or 500 ng recombinant VCP
protein, was incubated in 20 ml of the ATPase assay buffer (20 mMHEPES (pH 7.4),
50 mM KCl, 5 mM MgCl2) with 100 mM [c-32P]ATP (18.5 GBq/mmol)
(PerkinElmer) at 37uC for 20 min. After incubation, the reaction was quenched by
addition of 200 ml of 8% ice-cold trichloroacetic acid solution with 1 mM K2HPO4,
Figure 5 | in vivo efficacies of KUSs in the rd10 mouse model of retinitis pigmentosa. (a, c) Representative live sectional images (vertical sections)
by SD-OCT of retinas in 25- (a) and 29-day-old (c) normal C57BL/6 mouse (WT) and rd10 mice, administered KUS 121 (n5 17), KUS187 (n5 21), or
saline (n5 18) as a control. Vertical bars in the images indicate the thickness of outer nuclear layer (ONL). Note that the ONL was barely detectable in
saline-treated control rd10 mice. (b, d, f) Electroretinogram of 25- (b), 29- (d) and 33-day-old (f) normal C57BL/6 mouse (WT) and rd10 mice,
administered KUSs or saline. (e) HE-stained retinas of 33-day-old normal C57BL/6 mouse (WT) and rd10 mice, administered KUSs or saline. RPE:
retinal pigment epithelium. OS: outer segment. Scale bars (shown by white color), 100 mm in (a) and (c); 20 mm in (e). (g, h) Time-dependent changes of
total retinal thickness (g) and b-wave amplitude in dark-adapted electroretinogram (h) in rd10mice administered KUSs or saline. * P, 0.05, **P, 0.01,
*** P, 0.005 vs. saline (Dunnett’s test). Error bars indicate SD. (i)Western blot analysis of dissected retinas of 21-day-old rd10mice administered KUSs
or saline. WT: C57BL/6 control mice. Complete scans of the different blots are presented in Supplementary Fig. 10.
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and then 50 ml of solution A (3.75% ammonium molybdate, 0.02 M silicotungstic
acid in 3 N H2SO4) and 300 ml of n-butyl acetate were added to the reaction. The
samples were mixed well and centrifuged at 12,000 3 g for 1 min. Then, 200 ml
aliquots from the upper organic phases were taken and their radioactivity was
determined with a liquid scintillation counter for b-radiation, which determined the
amounts of 32P released.
Antibodies. Polyclonal antibodies against VCP were developed in our laboratory as
described previously12. Anti-Grp78, anti-Akt and anti-phospho-Akt (Ser 473)
antibodies were purchased from Cell Signaling (MA, USA); anti-tubulin, anti-CHOP
and anti-laminin c1 from Santa Cruz Biotechnology (CA, USA); anti-actin from
Chemicon (MA,USA); anti-ubiquitin fromMillipore (MA,USA), and anti-LC3 from
MBL (Nagoya, Japan).
Animal experiments. Animal experiments were conducted in accordance with the
Association Research in Vision and Ophthalmology (ARVO) Statement for the Use
of Animals in Ophthalmic and Vision Research. All protocols were approved by the
Institutional Review Board of the Kyoto University Graduate School of Medicine
(MedKyo11229). Rd10 mice22 were obtained from the Jackson Laboratory (Bar
Harbor, ME, USA). The environment was maintained at a 14-hour light/10-hour
dark cycle. All mice were fed ad libitum. Before image acquisition or
electroretinogram examination, the mice were anesthetized by an intraperitoneal
injection of pentobarbital (50 mg/kg body weight). Pupils were dilated to
approximately 2 mm in diameter using tropicamide and phenylephrine (0.5% each)
eye drops.
SD-OCT image acquisition and measurement of retinal thickness. Spectral-
domain optical coherence tomography (SD-OCT) examinations usingMultiline OCT
(Heidelberg Engineering, Heidelberg, Germany) were performed33 in rd10 mice at
ages of 21, 25, 29, and 33 days. Total retinal thickness (from inner limitingmembrane
to Bruchmembrane) in rd10mice wasmeasured using volume scan images33 within a
circle 0.366 mm in diameter, the center of which was adjusted to the center of the
optic nerve head. The mean value of the upper and lower quadrant was averaged.
Electroretinogram. Electroretinogram recording was performed to assess the visual
function of rd10 mice at ages of 21, 25, 29, and 33 days. Mice were dark-adapted
overnight before anesthetization. Electroretinograms were recorded using a gold loop
corneal electrode with a light-emitting diode (Mayo Corp., Inazawa, Japan). A
reference electrode was placed in the mouth and a ground electrode was inserted to
the anus. Stimuli were produced with a light emitting diode stimulator (Mayo Corp.).
The electroretinogram response signals were amplified, digitized at 10 kHz with a
band-pass filter of 0.3 to 500 Hz, and analyzed (PowerLab 2/25; AD instruments,
New South Wales, Australia). The a- and b-wave amplitudes and a-wave latency of
the mixed cone and rod response (ISCEV (International Society for Clinical
Electrophysiology of Vision) standard; scotopic 3.0)34 were analyzed.
Histological analyses. The eyes were fixed in 4% paraformaldehyde for 24 hours at
4uC and embedded in paraffin. Serial 6-mm paraffin-embedded sections that passed
through the center of the optic nerve head were selected. The selected retinal sections
were stained with hematoxylin-eosin (HE) and photographed about 400 mm apart
from the center of the optic nerve head under an optical microscope (Axioplan 2; Carl
Zeiss Jena GmbH, Jena, Germany). For electron microscopic examination, eyes were
fixed overnight in a mixture of 10% neutral buffered formalin and 2.5%
glutaraldehyde for 2.5 hours and subsequently fixed in 1% osmium tetroxide for
90 min. The retina was dehydrated through a graded series of ethanol (50–100%),
cleared in propylene oxide, and embedded in epoxy resin. Ultrathin sections were cut
by using an ultramicrotome and stained with uranyl acetate and lead citrate. The
stained sections were observed by transmission electron microscopy (H-7650,
Hitachi Co., Tokyo, Japan).
Statistical analysis.Variables among cells or mice treated with or without KUSs were
compared with Dunnett’s test or Student’s t-test. Statistical analyses were performed
using PASW Statistics version 17.0 (SPSS Inc., Chicago, IL). The level of statistical
significance was set at P , 0.05.
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